106 related articles for article (PubMed ID: 16920896)
1. Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.
Samuelsson S; Johansson S; Halldórsdóttir S; Stenhoff H; Ohman KP
J Clin Pharmacol; 2006 Sep; 46(9):1017-22. PubMed ID: 16920896
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP
Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
[TBL] [Abstract][Full Text] [Related]
3. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
5. Tesaglitazar.
Kamber N; Davis TM
IDrugs; 2005 Nov; 8(11):927-35. PubMed ID: 16254788
[TBL] [Abstract][Full Text] [Related]
6. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
[TBL] [Abstract][Full Text] [Related]
7. Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.
Glinghammar B; Berg AL; Bjurström S; Stockling K; Blomgren B; Westerberg R; Skånberg I; Hellmold H; Andersson U
Toxicol Pathol; 2011 Feb; 39(2):325-36. PubMed ID: 21270424
[TBL] [Abstract][Full Text] [Related]
8. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
[TBL] [Abstract][Full Text] [Related]
9. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
Fagerberg B; Edwards S; Halmos T; Lopatynski J; Schuster H; Stender S; Stoa-Birketvedt G; Tonstad S; Halldórsdóttir S; Gause-Nilsson I
Diabetologia; 2005 Sep; 48(9):1716-25. PubMed ID: 16001233
[TBL] [Abstract][Full Text] [Related]
10. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
Fagerberg B; Schuster H; Birketvedt GS; Tonstad S; Ohman KP; Gause-Nilsson I;
Diab Vasc Dis Res; 2007 Sep; 4(3):174-80. PubMed ID: 17907107
[TBL] [Abstract][Full Text] [Related]
11. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
Hellmold H; Zhang H; Andersson U; Blomgren B; Holland T; Berg AL; Elebring M; Sjögren N; Bamberg K; Dahl B; Westerberg R; Dillner B; Tugwood J; Tugwood J; Roberts R; Lundholm E; Camejo G; Skånberg I; Evans J
Toxicol Sci; 2007 Jul; 98(1):63-74. PubMed ID: 17468185
[TBL] [Abstract][Full Text] [Related]
12. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
[TBL] [Abstract][Full Text] [Related]
13. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Schuster H; Fagerberg B; Edwards S; Halmos T; Lopatynski J; Stender S; Birketvedt GS; Tonstad S; Gause-Nilsson I; Halldórsdóttir S; Ohman KP;
Atherosclerosis; 2008 Mar; 197(1):355-62. PubMed ID: 17631296
[TBL] [Abstract][Full Text] [Related]
14. Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
Lindblom P; Berg AL; Zhang H; Westerberg R; Tugwood J; Lundgren H; Marcusson-Ståhl M; Sjögren N; Blomgren B; Öhman P; Skånberg I; Evans J; Hellmold H
Toxicol Pathol; 2012; 40(1):18-32. PubMed ID: 22131108
[TBL] [Abstract][Full Text] [Related]
15. Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
Oakes ND; Thalén P; Hultstrand T; Jacinto S; Camejo G; Wallin B; Ljung B
Am J Physiol Regul Integr Comp Physiol; 2005 Oct; 289(4):R938-46. PubMed ID: 16183630
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
Ratner RE; Parikh S; Tou C;
Diab Vasc Dis Res; 2007 Sep; 4(3):214-21. PubMed ID: 17907111
[TBL] [Abstract][Full Text] [Related]
17. Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats.
Liao J; Soltani Z; Ebenezer P; Isidro-Carrión AA; Zhang R; Asghar A; Aguilar E; Francis J; Hu X; Ferder L; Reisin E
Nephron Exp Nephrol; 2010; 114(2):e61-8. PubMed ID: 19887847
[TBL] [Abstract][Full Text] [Related]
18. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.
Skrumsager BK; Nielsen KK; Müller M; Pabst G; Drake PG; Edsberg B
J Clin Pharmacol; 2003 Nov; 43(11):1244-56. PubMed ID: 14551179
[TBL] [Abstract][Full Text] [Related]
19. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus.
Hamrén B; Ohman KP; Svensson MK; Karlsson MO
J Clin Pharmacol; 2012 Sep; 52(9):1317-27. PubMed ID: 22045829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
